DiaMedica-Logo.png
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 16h35 HE | DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II...
DiaMedica-Logo.png
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
12 août 2019 08h00 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference,...
DiaMedica-Logo.png
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
08 août 2019 16h00 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
19 juin 2019 16h04 HE | DiaMedica Therapeutics Inc.
Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney...
DiaMedica-Logo.png
DiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019
22 mai 2019 09h30 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
21 mai 2019 08h34 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 21, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update
13 mai 2019 16h48 HE | DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019 at 7am CT MINNEAPOLIS,...
DiaMedica-Logo.png
DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
06 mai 2019 08h54 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on Monday,...
DiaMedica-Logo.png
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
30 avr. 2019 16h58 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
18 mars 2019 13h56 HE | DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March...